Allianz Asset Management GmbH Sells 16,045 Shares of DaVita Inc. (NYSE:DVA)

Allianz Asset Management GmbH reduced its position in shares of DaVita Inc. (NYSE:DVA) by 2.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 534,143 shares of the company’s stock after selling 16,045 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.65% of DaVita worth $79,881,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. MML Investors Services LLC raised its stake in shares of DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after acquiring an additional 68 shares during the last quarter. Exchange Traded Concepts LLC raised its position in DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock valued at $133,000 after purchasing an additional 68 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in DaVita by 1.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock worth $776,000 after buying an additional 70 shares during the period. Impact Partnership Wealth LLC grew its position in shares of DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after buying an additional 70 shares during the last quarter. Finally, Contravisory Investment Management Inc. increased its stake in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock valued at $910,000 after buying an additional 73 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Separately, Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus target price of $162.80.

DaVita Stock Down 2.5 %

DVA stock opened at $142.33 on Friday. DaVita Inc. has a fifty-two week low of $120.78 and a fifty-two week high of $179.60. The company has a market capitalization of $11.39 billion, a price-to-earnings ratio of 13.25, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94. The business’s 50 day moving average price is $161.03 and its two-hundred day moving average price is $157.86. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.